-+ 0.00%
-+ 0.00%
-+ 0.00%

Cabaletta Bio reports rese-cel activity without preconditioning in RESET-PV pemphigus trial

PUBT·05/04/2026 10:06:34
Listen to the news
Cabaletta Bio reports rese-cel activity without preconditioning in RESET-PV pemphigus trial
  • Cabaletta Bio plans to present new clinical and translational data May 14, 2026 at ASGCT from 4 refractory pemphigus vulgaris patients in RESET-PV treated with rese-cel at lowest dose without preconditioning.
  • Data showed biological activity with signs of clinical benefit in some patients despite stopping other immune-modulating medicines, supporting feasibility of dosing without chemotherapy-based preconditioning.
  • Safety profile appeared manageable at this dose, with mild cytokine release syndrome in one patient and no neurotoxicity reported.
  • Company has enrolled additional patients at a higher dose in RESET-PV, with durability readout expected in second half of 2026.
  • In lupus study RESET-SLE using same no-preconditioning approach, initial dose cohort is fully enrolled with initial data expected in first half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-202389), on May 04, 2026, and is solely responsible for the information contained therein.